• Search History (Register)
  • MeSH Browser
  • [Clear]
    • Canada

Welcome to the international HTA database


Showing [3321 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2015     Institut national d'excellence en sante et en services sociaux (INESSS) [Review process of matricial requirements for acute care facilities in the Quebec traumatology network]
2015     Institut national d'excellence en sante et en services sociaux (INESSS) [Investigation, treatment and monitoring algorithms for prostate cancer]
2015     Health Quality Ontario (HQO) Mitral valve clip for treatment of mitral regurgitation: OHTAC recommendation
2015     Health Quality Ontario (HQO) Mitral valve clip for treatment of mitral regurgitation: an evidence-based analysis
2015     Institut national d'excellence en sante et en services sociaux (INESSS) [Reablement for seniors experience a loss of autonomy]
2015     Institut national d'excellence en sante et en services sociaux (INESSS) [Information brief concerning palliative care day centres]
2015     Institut national d'excellence en sante et en services sociaux (INESSS) [Insulin pumps in the treatment of type 1 diabetes]
2015     Institute of Health Economics (IHE) A systematic review of the measurement properties of self-report instruments that assess presenteeism
2015     Canadian Agency for Drugs and Technologies in Health (CADTH) Public health interventions to reduce the secondary spread of measles
2015     Canadian Agency for Drugs and Technologies in Health (CADTH) Long-term use of acamprosate calcium for alcoholism: a review of the clinical effectiveness, safety, and guidelines
2015     Technology Assessment at SickKids (TASK) A cost-effectiveness analysis of maternal genotyping to guide treatment for postpartum pain and avert infant adverse events
2015     Canadian Agency for Drugs and Technologies in Health (CADTH) Perceval S sutureless valve for aortic valve replacement: a review of the clinical effectiveness, safety, and cost-effectiveness
2015     Canadian Agency for Drugs and Technologies in Health (CADTH) Rituximab for granulomatosis with polyangiitis or microscopic polyangiitis: a review of the clinical and cost-effectiveness
2015     Canadian Agency for Drugs and Technologies in Health (CADTH) Excimer laser and stenting in patients with distal peripheral arterial disease: a review of the clinical effectiveness, safety, and guidelines
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Apixaban and rivaroxaban for stroke prevention in atrial fibrillation: safety
2014     Health Quality Ontario (HQO) Health care for people approaching the end of life: an evidentiary framework
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Conjugate pneumococcal vaccine (13-Valent) for immunocompromised populations: a review of the clinical evidence
2014     Health Quality Ontario (HQO) Cardiopulmonary resuscitation in patients with terminal illness: an evidence-based analysis
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Bronchial thermoplasty for severe asthma: clinical and cost-effectiveness, and guidelines
2014     Health Quality Ontario (HQO) The determinants of place of death: an evidence-based analysis
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Disposable surgical gowns and wrappers: clinical and cost-effectiveness, and guidelines
2014     Health Quality Ontario (HQO) Educational intervention in end-of-life care: an evidence-based analysis
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Loop recorders to detect atrial arrhythmias in patients post-discharge who have had a cryptogenic stroke: a review of clinical and cost-effectiveness
2014     Health Quality Ontario (HQO) End-of-life care interventions: an economic analysis
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Third-line pharmacotherapy for type 2 diabetes erratum
2014     Health Quality Ontario (HQO) Patient care planning discussions for patients at the end of life: an evidence-based analysis
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Case management for vulnerable or homeless persons: clinical and cost-effectiveness, and guidelines
2014     Health Quality Ontario (HQO) Team-based models for end-of-life care: an evidence-based analysis
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Diagnostic computed tomography angiography for adult patients: safety
2014     Health Quality Ontario (HQO) Effect of supportive interventions on informal caregivers of people at the end of life: a rapid review
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Nitroglycerin for the treatment of pulmonary edema following submersion: clinical effectiveness and guidelines
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Vitamin D testing for northern populations: clinical and cost-effectiveness and guidelines
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Long-term use of ranibizumab for the treatment of age-related macular degeneration: a review of the clinical and cost-effectiveness and guidelines
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Alcohol with chlorhexidine hand sanitizers: clinical effectiveness and guidelines
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Vancomycin-resistant enterococci isolation and screening strategies: clinical evidence and cost-effectiveness
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Mobile x-ray imaging versus fixed x-ray imaging in long-term care: clinical and cost-effectiveness
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Dutasteride and finasteride for men with benign prostatic hyperplasia: comparative clinical effectiveness and safety
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Ingenol mebutate (Picato - LEO Pharma Inc.) indication: actinic keratosis
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Clinical review report. Ingenol mebutate (Picato LEO Pharma Inc.) indication: topical treatment of non-hyperkeratotic, non-hypertrophic actinic keratosis in adults
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Pharmacoeconomic review report. Ingenol mebutate (Picato LEO Pharma Inc.) indication: topical treatment of non-hyperkeratotic, non-hypertrophic actinic keratosis in adults
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Ketamine for adult patients who have suffered painful and traumatic injuries: a Review of Clinical Effectiveness, Cost-Effectiveness, Safety and Guidelines
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Plasma Vaporization of the Prostate for Treatment of Benign Prostatic Hypertrophy: A review of clinical and cost-effectiveness, and safety
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Computed tomography scanners for patients in rural or remote locations: clinical and cost-effectiveness
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) The ABCD2 scoring system for transient ischemic attacks: a review of the diagnostic accuracy and predictive value
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Fall risk assessment in adult patients: comparative evidence and guidelines
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Endoscopic ultrasound for the diagnosis of disease and staging of cancers in adult patients with gastroenterological or oncological disease: guidelines
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Mobilization of adult inpatients in hospitals or long-term/chronic care facilities: benefits and harms, safety, and guidelines
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Hepatitis C polymorphism testing: a review of the clinical evidence
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Platelet rich plasma lumbar disc injections for lower back pain: clinical effectiveness, safety, and guidelines
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Oncotype DX in women and men with ER-positive, HER2-negative early stage breast cancer who are lymph node negative: a review of clinical effectiveness and guidelines
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Tiotropium bromide
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Diabetes care for indigenous populations: a review of the clinical evidence and guidelines
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Digital tomosynthesis for the screening and diagnosis of breast cancer: diagnostic accuracy and guidelines
2014     Agence d'évaluation des technologies et des modes d'intervention en santé (AETMIS) [Field evaluation of the initial treatment of STEMI in Quebec's hospitals - phase 2]
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Bolused (vice infused) tranexamic acid in adults experiencing hemorrhagic shock: safety, patient benefits, and guidelines
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Frequency of rescreening of patients negative for antibiotic resistant organisms: clinical evidence and guidelines
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Ocriplasmin (Jetrea - Alcon Canada Inc.) indication: symptomatic vitreomacular adhesion
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Intravenous administration of medications in home care settings: clinical evidence and guidelines
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Clinical review report. Ocriplasmin (Jetrea - Alcon Canada Inc.) indication: symptomatic vitreomacular adhesion
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Urine testing in long-term care: clinical and cost effectiveness
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Pharmacoeconomic review report. Ocriplasmin (Jetrea - Alcon Canada Inc.) indication: symptomatic vitreomacular adhesion
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Continuous positive airway pressure compared with oral devices or lifestyle changes for the treatment of obstructive sleep apnea: a review of the clinical and cost-effectiveness
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Somatropin (Genotropin - Pfizer Canada Inc.) indication: Turner syndrome
2014     Health Quality Ontario (HQO) Testing vitamin B12 levels in neuropathy, alopecia, dizziness, and fatigue: a rapid review
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Parent advisors in pediatric rehabilitation: clinical effectiveness and guidelines
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Clinical review report. Somatropin (Genotropin - Pfizer Canada Inc.) indication: Turner syndrome
2014     Health Quality Ontario (HQO) Preoperative consultation: a rapid review
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Universal screening for antibiotic-resistant organisms in long-term care facilities: clinical effectiveness and guidelines
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Pharmacoeconomic review report. Somatropin (Genotropin - Pfizer Canada Inc.) indication: Turner syndrome
2014     Health Quality Ontario (HQO) Preoperative cardiac stress tests for noncardiac surgery: a rapid review
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Linaclotide
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Pharmacoeconomic review report. Somatropin (Genotropin - Pfizer Canada Inc.) indication: long-term treatment of children who have growth failure due to an inadequate secretion of endogenous growth hormone
2014     Health Quality Ontario (HQO) Preoperative resting echocardiography for noncardiac surgery: a rapid review
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Dexmedetomidine for sedation in the ICU or PICU: a review of cost-effectiveness and guidelines
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Clinical review report. Somatropin (Genotropin - Pfizer Canada Inc.) indication: long-term treatment of children who have growth failure due to an inadequate secretion of endogenous growth hormone
2014     Health Quality Ontario (HQO) Hemoglobin A1c testing in diabetes: a rapid review
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Autologous blood reinfusion system for orthopedic surgery: clinical and cost-effectiveness
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Somatropin (Genotropin - Pfizer Canada Inc.) indication: long-term treatment of children who have growth failure due to an inadequate secretion of endogenous growth hormone
2014     Institute of Health Economics (IHE) Effectiveness of screening for endemic antibiotic resistant organisms (AROs) in hospital settings
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Extracorporeal membrane oxygenation for acute respiratory failure: a review of the clinical effectiveness and guidelines
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Vitamin D toxicity associated with different vitamin D dosing regimens: safety
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Clinical review report. Somatropin (Genotropin - Pfizer Canada Inc.) indication: growth hormone deficiency in adults
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Extracorporeal membrane oxygenation for cardiac failure: a review of the clinical effectiveness and guidelines
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Pharmacoeconomic review report. Somatropin (Genotropin - Pfizer Canada Inc.) indication: growth hormone deficiency in adults
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Post-operative cerebrospinal fluid removal: guidelines
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Lurasidone (Latuda - Sunovion Pharmaceuticals Inc.) indication: schizophrenia
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Islet cell transplantation in patients with unstable diabetes: a review of clinical- and cost-effectiveness and guidelines
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Clinical review report. Lurasidone (Latuda - Sunovion Pharmaceuticals Inc.) indication: schizophrenia
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Azelastine - HCl and fluticasone propionate
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Pharmacoeconomic review report. Lurasidone (Latuda - Sunovion Pharmaceuticals Inc.) indication: schizophrenia
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Urine testing in long-term care: guidelines
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Lyophilized plasma for the treatment of adults with hemorrhagic shock: clinical and cost-effectiveness, safety, and guidelines
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Retinal surgeries in non-hospital facilities: clinical and cost-effectiveness
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Suboxone versus methadone for the detoxification of patients addicted to prescription opioids: a review of comparative clinical effectiveness, safety, and guidelines
2014     Institut national d'excellence en sante et en services sociaux (INESSS) [Addendum to the notice on the efficacy of rehabilitative interventions and pharmacological therapies for children aged 2 to 12 Years with autism spectrum disorder (ASD)]
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Viscosupplementation for the treatment of osteoarthritis of the knee: clinical effectiveness and guidelines
2014     Institut national d'excellence en sante et en services sociaux (INESSS) [Change in the Proton Pump Inhibitors (PPI) terms for coverage: a follow-up]
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Immediate initiation of continuous positive airway pressure compared with delayed initiation: clinical effectiveness and guidelines
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) iTClamp for controlling compressible gemorrhage in adults: clinical effectiveness, cost-effectiveness, and safety
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Triple therapy for hepatitis C in previous non-responders: a review of the clinical effectiveness and safety